Ó³»­´«Ã½

The Genomics Platform has its roots in the Whitehead Institute Center for Genome Research, which was the single-largest contributor to the Human Genome Project. More recently, the platform has been one of the world's largest producers of human genomic information, and during the SARS-CoV-2 pandemic was one of the largest producers of COVID-19 diagnostic test results anywhere. The platform follows a path of ambitious achievement aimed at recognizing the promise of genomic medicine in the United States and throughout the world.

Data generated by the Genomics Platform has enabled a wide range of applications, from variant discovery to delivery of polygenic risk scores and clinical diagnoses, and contributed knowledge to a wide array of fields, from rare disease research to population genomics, from cancer clinical trials to understanding cell circuitry.

Ó³»­´«Ã½ Clinical Labs (BCL)

(BCL), a CLIA-licensed and CAP-accredited wholly owned subsidiary of the Ó³»­´«Ã½, offers a range of that empower multi-omic data generation and analysis needs, both for the Ó³»­´«Ã½ research community and for the rest of the world. Ó³»­´«Ã½ Clinical Labs is the LLC through which the Genomics Platform’s services are offered to users in the United States and throughout the world.

Accessing our services

BCL’s services include both research and clinical-grade offerings and range from whole genome sequencing, whole exome sequencing, blended genome-exome sequencing, and bulk RNA sequencing, to single cell sequencing, isoform sequencing, liquid biopsy/cfDNA profiling, plasma proteomic profiling, and sequencing of customer-prepared libraries.

Customers and collaborators can contact us to get started and find more details on our services at the .